Toxic epidermal necrolysis as a complication of treatment with voriconazole

Southern Medical Journal

Volumn 97, Issue 11, 2004, Pages 1116-1117

  Huang, David B ^a   Wu, Jashin J ^a   Lahart, Christopher J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Toxic epidermal necrolysis; Voriconazole

Indexed keywords

IMMUNOGLOBULIN; VORICONAZOLE;

AGED; ARTICLE; CANDIDA KRUSEI; CANDIDIASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DOSE TIME EFFECT RELATION; ECHOGRAPHY; FEMALE; GASTROINTESTINAL BIOPSY; HISTOPATHOLOGY; HUMAN; JAUNDICE; SKIN BIOPSY; SKIN MANIFESTATION; SYMPTOMATOLOGY; TOXIC EPIDERMAL NECROLYSIS; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PYRIMIDINES; TRIAZOLES;

EID: 8744244337     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000144618.80128.F9     Document Type: Article

References (13)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-1285.
2. Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42.
3. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-1607.
4. Becker DS. Toxic epidermal necrolysis. Lancet 1998;351:1417-1420.
5. Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002;11:409-429.
6. Gallagher JC, Dodds Ashley ES, et al. Antifungal pharmacotherapy for invasive mould infections. Expert Opin Pharmacother 2003;4:147-164.
7. Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003;36:1122-1131.
8. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
9. Ghannoum MA, Kuhn DM. Voriconazole: better chances for patients with invasive mycoses. Eur J Med Res 2002;7:242-256.
10. Walsh TJ, Lutsar I, Driscoll T, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002;21:240-248.
11. Spielberg SP, Gordon GB, Blake DA, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;305:722-727.
12. Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105:179-184.
13. Wolkenstein P, Charue D, Laurent P, et al. Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995;131:544-551.